Background: Twenty-four hours dynamic blood pressure (BP) behaviour displays dipper profile defined as nocturnal systolic BP (SBP) reduction>10% compared to daytime. Non-dipper profile, nocturnal absence of SBP fall, associates an increased cardiovascular risk. We investigated the concomitant association of inflammatory bio-markers - high-sensitivity- C-reactive protein (hs-CRP), Human Chitinase3-like1 (YKL-40) and autonomic nervous system (total brain-derived neurotrophic factor, BDNF) with respect to non-dipping blood pressure status.
Material and method: Using 24h automatic BP measurements, 80 known hypertensive patients were divided into two groups: dipper group included fifty-one dipper patients (age 55.6 ±13.5 years) and non-dipper group consisted of 29 non-dipper subjects (62.07±12.03 years). Serum levels of hs-CRP were evaluated with enhanced immunoturbidimetric assay. Plasma levels of YKL-40 were measured by commercial sandwich ELISA using microplate coated with a monoclonal antibody for CHI3L1. Plasma levels of total BDNF were determined using quantitative sandwich enzyme-linked immunoassay. Statistical analysis of obtained data was performed.
Results: In the non-dipper group, a significant positive association with age over 60 years, hs-CRP values above 1.90 mg/dl was observed along with increased mean values of YKL-40. Non-dipper status is independently and statistically significantly associated with elevated levels of hs-CRP (OR: 3.248, 95% CI: 1.022-10.317, p=0.046) in multivariate odds ratio analysis. No statistically significant positive association between a median total BDNF plasma level of 1430 pg/ml and the non-dipper hypertension profile was identified.
Conclusion: Our study demonstrated that patients over 60 years, in particular, have a higher probability to present a non-dipping pattern of hypertension. hs-CRP and YKL-40 values are more likely to increase in the non-dipping hypertensive patients, and hs-CRP values above 1.9 mg/dl can identify the presence of a non-dipper blood pressure profile.
1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 pii: HYP.0000000000000065.
2. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. J Hypertens Suppl. 1991;9(8):S42-4.
3. Karadag B, Ozyigit T, Serindag Z, Ilhan A, Ozben B. Blood pressure profile is associated with microalbuminuria and retinopathy in hypertensive nondiabetic patients. Wien Klin Wochenschr. 2017. DOI: 10.1007/s00508-017-1270-3. (Epub ahead of print). DOI: 10.1007/s00508-017-1270-3
4. Tsivgoulis G, Pikilidou M, Katsanos AH, Stamatelopoulos K, Michas F, Lykka A et al. Association of ambulatory blood pressure monitoring parameters with the Framingham Stroke Risk Profile. J Neurol Sci. 2017;380:106-111. DOI: 10.1016/j.jns.2017.07.007
5. Sekizuka H, Osada N, Akashi YJ. The factors affecting the non-dipper pattern in japanese patients with severe obstructive sleep apnea. Intern Med. 2018;57(11):1553-9. DOI: 10.2169/internalmedicine.0029-17
6. Cachofeiro V, Miana M, Heras N, Martin-Fernandez B, Ballesteros S, Balfagon G, et al. Inflammation: a link between hypertension and atherosclerosis. Curr Hypertens Rev. 2009;5(1):40-8. DOI: 10.2174/157340209787314333
7. Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ et al. – Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling and injury. Ann Rev Physiol. 2011;73:479-501. DOI: 10.1146/annurev-physiol-012110-142250
8. Rathcke CN, Vestergaard H. YKL-40 – an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. DOI: 10.1186/1475-2840-8-61
9. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42(5):295–302. DOI: 10.1080/14017430802220567
10. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J. 2009;30(9):1066–72. DOI: 10.1093/eurheartj/ehp049
11. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis. 2007;18(5):391–6. DOI: 10.1097/MCA.0b013e328241d991
12. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace. 2009;11(8):1032–6. DOI: 10.1093/europace/eup103
13. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172-209.
14. Xu T, Zhong C, Wang A, Guo Z, Bu X, Zhou Y, et al. YKL-40 Level and hypertension incidence: a population-based nested. case-control study in China. J Am Heart Assoc. 2016;5(11):e004534. DOI: 10.1161/JAHA.116.004534
15. Churakova E, Shubina A; Bolotina, M, Masenko V, Karpov Y. New inflammatory marker YKL-40 is associated with early renal function decline in hypertensive patients with concomitant coronary artery disease and type 2 diabetes mellitus. J Hypertens. 2017;35, e-Supplement 2.
16. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framing-ham Offspring Study. Circulation. 2004;110(4):380-5. DOI: 10.1161/01.CIR.0000136581.59584.0E
17. Shu HS, Tai YY, Chang KT, Chu CY, Hsu PC, Ho-Ming Su, et al. Plasma high-sensitivity C-reactive protein level is associated with impaired estimated glomerular filtration rate in hypertensives. Acta Cardiol Sin 2015;31(2):91-7.
18. Buyukkaya E, Erayman A, Karakas E, Bugra Nacar A, Kurt M, Buyukkaya S, et al – Relation of red cell distribution width with dipper and non-dipper hypertension. Med Glas (Zenica) 2016;13(2):75-81.
19. Pius-Sadowska E, Machaliński B. BDNF - A key player in cardiovascular system. J Mol Cell Cardiol. 2017;110:54-60. DOI: 10.1016/j.yjmcc.2017.07.007. DOI: 10.1016/j.yjmcc.2017.07.007
20. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hyper-tens. 2002;15 (2 Pt 1):111–8. DOI: 10.1016/S0895-7061(01)02251-8
21. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2013;34(28):2159–219. DOI: 10.1093/eurheartj/eht151
22. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24(6):793-801. DOI: 10.1161/01.HYP.24.6.793
23. Niiranen TJ, Jula AM, Kantola IM, Reunanen A. Comparison of agreement between clinic and home-measured blood pressure in the Finnish population: the Finn-HOME Study. J Hypertens. 2006;24(8):1549-55. DOI: 10.1097/01.hjh.0000239290.94764.81
24. Liu X, Liu C, Schenck H, Yi X, Wang H, Shi x. The risk factors of 9-year follow-up on hypertension in middle-aged people in Tujia-Nationality settlement of China. J Hum Hypertens. 2017;31(12):838-42. DOI: 10.1038/jhh.2017.58
25. Habibzadeh F, Habibzadeh P, Yadollahi M. On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochem Med (Zagreb). 2016; 26(3): 297–307. DOI: 10.11613/BM.2016.034
26. Jimenez MC, Rexrode KM, Kotler G, Everett BM, Glynn RJ, Lee IM et al. Association between markers of inflammation and total stroke by hypertensive status among women. Am J Hypertens. 2016;29(9):1117-24. DOI: 10.1093/ajh/hpw050
27. Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, Porreca E. Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients. Hypertens Res. 2016;39(11):805–11. DOI: 10.1038/hr.2016.74
28. Pierdomenico SD, Pierdomenico AM, Di Tommaso R, Coccina F, Di Carlo S, Ettore Porreca E, et al. Morning blood pressure surge, dipping, and risk of coronary events in elderly treated hypertensive patients. Am J Hypertens. 2016;29(1):39-45. DOI: 10.1093/ajh/hpv074
29. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397-408. DOI: 10.1016/j.jacc.2013.05.016
30. Tosu AR, Demir S, Selcuk M, Kaya Y, Akyol A, Ozdemir M, et al. Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej. 2014;10(2): 98–103. DOI: 10.5114/pwki.2014.43514
31. Bakirci EM, Degirmenci H, Hamur H, Gunay M, Gulhan B, Aydin M, et al. – New inflammatory markers for prediction of non-dipper blood pressure pattern in patients with essential hypertension: Serum YKL-40/Chitinase 3-like protein 1 levels and echocardiographic epicardial adipose tissue thickness. Clin Exp Hypertens. 2015;37(6):505-10. DOI: 10.3109/10641963.2015.1013122
32. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221-7. DOI: 10.1007/s00011-006-0076-y
33. Vermehren-Schmaedick A, Jenkins VK, Hsieh HY, Brown AL, Page MP, Brooks VL, et al. Upregulation of brain-derived neurotrophic factor expression in no-dose ganglia and the lower brainstem of hypertensive rats. J Neurosci Res 2013;91(2):220–9. DOI: 10.1002/jnr.23158
34. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328(3): 261–4. DOI: 10.1016/S0304-3940(02)00529-3
35. Hojo Y, Noma S, Ohki T, Nakajima H, Satoh Y. Autonomic nervous system activity in essential hypertension: a comparison between dippers and non-dippers. J Hum Hypertens. 1997;11:665–71. DOI: 10.1038/sj.jhh.1000515
36. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hyper-tens. 2002;15(2 Pt1): 111–8. DOI: 10.1016/S0895-7061(01)02251-8
37. Kasselman LJ, Sideris A, Bruno C, Perez WR, Cai N, Nicoletti JN, et al. BDNF: a missing link between sympathetic dysfunction and inflammatory disease? J Neuroimmunol. 2006;175(1-2):118-27. DOI: 10.1016/j.jneuroim.2006.03.008
38. Kadoya M, Koyama H, Kanzaki A, Kurajoh M, Hatayama M, Shiraishi J, et al. Plasma brain-derived neurotrophic factor and reverse dipping pattern of nocturnal blood pressure in patients with cardiovascular risk factors. PLoS One. 2014;9(8):e105977. DOI: 10.1371/journal.pone.0105977